MYX2449 / Myricx Pharma - LARVOL DELTA

Francis Crick and ICL spinout raises £90m to clinically develop cancer treatments (PharmaTimes) - "The Francis Crick Institute and Imperial College London (ICL) cancer therapy spinout, Myricx Bio, has raised £90m in series A financing to advance its novel cancer treatments into clinical development...The investment will help to develop the company’s therapies to treat a range of different tumour types, including breast, lung and colorectal cancer, to advance into clinical testing...The spinout is focused on the discovery and development of a novel class of payloads for antibody-drug conjugates..."

Financing • Breast Cancer • Colorectal Cancer • Lung Cancer

Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates (PRNewswire) - "Novo Holdings...today announces that it has co-led a £90 million ($114 million) Series A financing for Myricx Bio ('Myricx'), the largest European biotech Series A financing this year...The funds will be used to advance Myricx's proprietary pipeline of N-Myristoyltransferase inhibitor (NMTi) ADCs through clinical proof of concept, targeting clinically validated tumor-associated antigens and addressing serious unmet needs in oncology."

Financing • Oncology

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics (GlobeNewswire) - "Myricx Bio...today announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms. Under the terms of the agreement, Myricx will develop the antibody into a first-in-class ADC based on its NMTi payload platform...including microtubule and topoisomerase inhibitors. Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours. WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales."

Licensing / partnership • Solid Tumor

Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class (GlobeNewswire) - "Myricx Bio...is presenting preclinical in vivo efficacy data for its NMTi-ADC platform and pipeline at the 14th Annual World ADC Event, San Diego, California, held from October 16-19, 2023....In the poster presentation Myricx reported data for three NMTi-ADCs in its pipeline. These comprise B7-H3-NMTi, TROP2-NMTi, and HER2-NMTi. B7-H3-NMTi demonstrated complete and durable tumour regressions in multiple models of aggressive prostate cancer refractory to Topo1i-based ADCs....TROP2-NMTi also demonstrated complete and durable tumour regressions in breast cancer models refractory to Topo1i-based ADCs; including the ability to regress large and established tumours that had prior exposure to a Topo1i-based ADC. HER2-NMTi demonstrated complete efficacy, and an encouraging tolerability profile in rodents and non-human primates."

Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

N-Myristolytransferase (NMT) inhibitors as novel potent payloads for Antibody Drug Conjugates (ADC) (EACR 2023) - "ADCs were tested in vitro in cytotoxicity studies using Her2+ and Her2- cell lines and subsequently tested in vivo in breast and gastric cancer xenografts.Results and DiscussionsTreatment with our first Trastuzumab-NMT inhibitor ADC (MYX-2449) resulted in cytotoxicity in Her2+ BT474 cells with an EC50 of 0.2nM, with no cell death observed in the B12 isotype control at concentrations tested (50nM and below). NMT inhibitors represent a totally novel class of ADC payloads that exploit cancer cell dependency on N-myristoylated proteins. The potential of this novel mechanism to deliver high efficacy with better TI is currently being investigated in preclinical models."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi (GlobeNewswire) - "Myricx’s novel highly potent NMTi are selectively cytotoxic in multiple cancer cell lines as well as exhibiting tumour regression in in vivo models of both haematological and solid cancers....Myricx’s most advanced ADC, MYX2449, is a selective and ultrapotent NMTi conjugated via a cleavable linker to trastuzumab (HER2+ mAb). Positive in vitro and in vivo data presented at AACR demonstrate MYX2449 cytotoxic potency in selective cancer cell lines, anti-tumour efficacy in both high and low HER2 expressing cancers, with tolerability >10 times its efficacious dose in in vivo models."

Preclinical • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Solid Tumor